Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 111 positions · Total reported value $1.86B · Top-10 concentration 50.3% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 61.5% · 24 new · 32 cut · 32 exited

Active Share (vs S&P 500): 99.1% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -9.4% · vs SPY -11.5% · Prev Value $1.91B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.0% · vs SPY -2.2% · Latest Value $1.86B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Eversept Partners, LP disclosed 111 equity positions with a combined reported value of $1.86B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were UTHR ($175.97M), EHC ($131.49M), ENSG ($124.90M). By sector, the heaviest allocations are Health Care 79.0%, Real Estate 7.0%. Versus the prior quarter, allocation shifted toward Industrials (+5.2pp), Other (+2.5pp) and away from Consumer Discretionary (-0.7pp), Health Care (-9.3pp).

Versus the prior quarter, Eversept Partners, LP opened 24 new positions, trimmed 32 and fully exited 32, a turnover rate of 61.5% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q3 2026 were GH ($45.74M), WAT ($33.14M), GRAL ($25.52M).

Of the 32 positions fully exited versus the prior quarter, the largest were GSK ($25.26M), LLY ($24.13M), AMN ($13.87M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GH GUARDANT HEALTH INC · $45.74M
  • WAT WATERS CORP · $33.14M
  • GRAL GRAIL INC · $25.52M
  • GDRX GOODRX HLDGS INC · $16.51M
  • ROIV ROIVANT SCIENCES LTD · $15.33M
  • SPY STATE STR SPDR S&P 500 ETF T · $15.25M
  • SUPN SUPERNUS PHARMACEUTICALS · $14.97M
  • ARWR ARROWHEAD PHARMACEUTICALS IN · $10.22M

Fully Exited (vs previous quarter)

  • GSK GSK PLC · prev qtr: $25.26M
  • LLY ELI LILLY & CO · prev qtr: $24.13M
  • AMN AMN HEALTHCARE SVCS INC · prev qtr: $13.87M
  • CELC CELCUITY INC · prev qtr: $13.38M
  • HUM HUMANA INC · prev qtr: $12.38M
  • ASND ASCENDIS PHARMA A/S · prev qtr: $11.10M
  • MRNA MODERNA INC · prev qtr: $10.65M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $10.22M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 79.0%
Technology 0.9%
Financials 0.0%
Other 6.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 324.73K $175.97M 9.46%
9.46%
Add
2 1.08M $131.49M 7.07%
7.07%
Add
3 726.19K $124.90M 6.71%
6.71%
Add
4 1.10M $108.99M 5.86%
5.86%
Add
5 135.00K $99.87M 5.37%
5.37%
Add
6 2.36M $76.27M 4.10%
4.10%
Add
7 449.79K $68.77M 3.70%
3.70%
Add
8 128.13K $52.96M 2.85%
2.85%
Reduce
9 1.35M $49.48M 2.66%
2.66%
Add
10 1.01M $46.71M 2.51%
2.51%
Add
11 2.44M $45.93M 2.47%
2.47%
Reduce
12 256.43K $45.74M 2.46%
2.46%
New
13 1.17M $38.07M 2.05%
2.05%
Reduce
14 75.42K $33.14M 1.78%
1.78%
New
15 1.01M $32.81M 1.76%
1.76%
Add
16 2.87M $31.05M 1.67%
1.67%
Reduce
17 68.32K $29.15M 1.57%
1.57%
Reduce
18 509.24K $28.98M 1.56%
1.56%
Reduce
19 453.87K $26.72M 1.44%
1.44%
Reduce
20 9.14M $26.13M 1.41%
1.41%
Add
21 182.15K $25.52M 1.37%
1.37%
New
22 18.53M $22.79M 1.23%
1.23%
Reduce
23 43.91K $22.18M 1.19%
1.19%
Reduce
24 536.05K $20.91M 1.12%
1.12%
Add
25 458.00K $19.63M 1.05%
1.05%
Add
26 1.02M $19.43M 1.04%
1.04%
Reduce
27 641.99K $19.43M 1.04%
1.04%
Add
28 160.81K $18.35M 0.99%
0.99%
Add
29 304.84K $18.29M 0.98%
0.98%
Add
30 279.85K $18.12M 0.97%
0.97%
Add
31 70.42K $18.00M 0.97%
0.97%
Reduce
32 5.02M $16.51M 0.89%
0.89%
New
33 480.11K $15.37M 0.83%
0.83%
Reduce
34 419.14K $15.33M 0.82%
0.82%
New
35 20.00K $15.25M 0.82%
0.82%
New
36 347.86K $14.97M 0.81%
0.81%
New
37 100.97K $13.17M 0.71%
0.71%
Reduce
38 64.82K $12.46M 0.67%
0.67%
Add
39 681.71K $12.30M 0.66%
0.66%
Add
40 46.19K $10.63M 0.57%
0.57%
Reduce
41 156.22K $10.22M 0.55%
0.55%
New
42 129.28K $10.16M 0.55%
0.55%
Add
43 3.54M $9.64M 0.52%
0.52%
Hold
44 526.65K $8.91M 0.48%
0.48%
New
45 211.74K $8.80M 0.47%
0.47%
Add
46 265.12K $8.41M 0.45%
0.45%
Reduce
47 154.92K $7.79M 0.42%
0.42%
Add
48 39.38K $7.45M 0.40%
0.40%
Reduce
49 484.05K $7.28M 0.39%
0.39%
Add
50 193.16K $7.26M 0.39%
0.39%
Add

FAQ

What did Eversept Partners, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Eversept Partners, LP reported 111 equity positions worth $1.86B in aggregate; its largest disclosed positions were UTHR ($175.97M), EHC ($131.49M), ENSG ($124.90M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.86B of long equity holdings across 111 positions as of 2026-Q3. Top-10 holdings account for 50.3% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →